Oncothyreon Stock Continues Climbing Ahead Of Presentation


Oncothyreon ONTY Stock NewsOncothyreon Inc (USA) (NASDAQ: ONTY)

Oncothyreon stock has had a great month in the market thus far; and it just keeps getting better. Following a press release that there will be a presentation from the company’s CEO, we’ve seen more bullish activity on the stock today. So below, we’ll talk about when and where the presentation will be, what we’re seeing from the stock today, and what we can expect to see from ONTY moving forward. Let’s get right to it…

Oncothyreon CEO To Present At The Jefferies 2015 Healthcare Conference

News broke today that the President and CEO of Oncothyreon, Robert Kirkman, M.D., will be giving a presentation on Wednesday, June 3rd at 11:30 am Eastern Time. The Presentation will be held in New York at the Jefferies 2015 Healthcare Conference. However, if you can’t make it to New York, you’re not out of luck. The presentation will be provided digitally through an archived webcast offered on the company’s website under the “News & Events” section.

What We Can Expect To See At The Presentation

Oncothyreon is a clinical-stage biopharmaceutical company with a strong focus on the development of therapeutic products for the treatment of cancer. The company currently has 2 main candidates…

  • ONT-380 – ONT-380 is an orally active and selective small molecule HER2 inhibitor.
  • ONT-10 – ONT-10 is a therapeutic vaccine designed to target MUC1.

It’s also important to mention that the company uses a proprietary protocell technology in an effort to develop more preclinical product candidates in the oncology field. With that being said, I’m expecting to see updates in all of these areas. Dr. Kirkman is likely to discuss both ONT-380 and ONT-10. I’m also expecting to learn more about potential product candidates discovered using the company’s proprietary technology.

What We’re Seeing From ONTY Today

As mentioned above, ONTY is doing very well in the market today following the news of the presentation. Currently (1:41), the stock is trading at $3.21 per share after a gain of 6.56%.

What We Can Expect From ONTY Moving Forward

Moving forward, I’m expecting to see good things from Oncothyreon stock in both the short term and long term outlooks. Here’s how I see it…

  • Short Term – In small-cap biotech stocks, news is the biggest mover of the market. With that said, ONTY’s President and CEO will be giving a presentation; and I’m expecting to see key updates to it’s candidates and possible additions to the line up. As a result, investors are likely to get excited and send the stock up!
  • Long Term – In the long run, I’m also expecting to see positivity. The company has sound management and a clear plan; coupled with a decent pipeline ta-boot. All in all, I’m expecting to see growth from ONTY.

What Do You Think?

Where do you think ONTY is headed and why? Let us know in the comments below!


Please enter your comment!
Please enter your name here